Innovative Immunotherapy in Advanced Basal Cell Carcinoma: Evolving Science, Key Clinical Evidence, and Implications for Multidisciplinary Management
1.50 hr(s) | ABIM , CME , CPE , MOC , NCPD
Specialty: Basal Cell Carcinoma
Therapeutic Area(s): Oncology
Release Date: June 4, 2021
Expiration Date: June 4, 2021
Location: Live Webcast
Basal cell carcinoma (BCC) is a commonly occurring skin malignancy that is easily treatable with surgery and/or radiation when detected at an early stage. However, advanced disease is typically associated with a poor prognosis and is often more challenging to treat, even with targeted agents (because of adverse events and the potential for acquired resistance). Advances in the understanding of BCC pathogenesis first suggested a role for immunotherapy via PD-1 blockade, and follow-up research has led to regulatory approval of immune treatment, including in patients who have progressed on or are unable to receive hedgehog pathway inhibitors. This “Seminars and Tumor Board” live web broadcast will provide an expert-led tour of the evidence that supports incorporating immunotherapy into existing treatment protocols for advanced BCC. Scientific lectures will be linked with practical, case-centered sessions designed to mimic the collaborative aspects of real-world, multidisciplinary tumor boards in order to clearly illustrate how oncologists can adapt their current practice and offer the power of immune-based treatment to patients with BCC. Register today to join us!